Skip to main content

Market Overview

PDL BioPharma Issues Downbeat Q3 Revenue Forecast

Share:

PDL BioPharma Inc (NASDAQ: PDLI) projected downbeat third-quarter revenue.

PDL BioPharma now projects Q3 revenue of $83 million, versus analysts' estimates of $88 million.

PDL BioPharma shares gained 0.17% to $5.80 in after-hours trading.

 

Related Articles (PDLI)

View Comments and Join the Discussion!

Posted-In: guidanceNews Guidance

Need corporate guidance data?
Click here to see licensing options.
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com